- Home
- OSS vs ELTX Comparison
OSS vs ELTX Comparison
Compare OSS & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OSS | ELTX |
|---|---|---|
| Founded | 1998 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 229.6M | 185.4M |
| IPO Year | 2017 | 2014 |
Fundamental Metrics
Financial Performance| Metric | OSS | ELTX |
|---|---|---|
| Price | $15.42 | $10.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $10.00 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 2.1M | 124.8K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 133.85 | 39.29 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $37,027,382.00 | $2,301,000.00 |
| Revenue This Year | $22.19 | N/A |
| Revenue Next Year | $20.67 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 34.46 | N/A |
| 52 Week Low | $2.37 | $5.80 |
| 52 Week High | $16.95 | $14.93 |
Technical Indicators
Market Signals| Indicator | OSS | ELTX |
|---|---|---|
| Relative Strength Index (RSI) | 75.79 | 47.63 |
| Support Level | $7.45 | $9.85 |
| Resistance Level | N/A | $12.00 |
| Average True Range (ATR) | 1.46 | 0.94 |
| MACD | 0.67 | -0.06 |
| Stochastic Oscillator | 82.15 | 27.97 |
Price Performance
Historical ComparisonAbout OSS One Stop Systems Inc.
One Stop Systems Inc designs, manufactures, and markets specialized rugged high-performance compute ("HPC"), high-speed switch fabrics, and storage systems, which are designed to target edge applications for artificial intelligence ("AI") / machine learning ("ML"), sensor processing, sensor fusion, and autonomy.
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.